lung cancer
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
Daiichi’s lung cancer drug progresses to phase III
August 5, 2010Research and Development Daiichi, arq 197, arqule, lung cancer, phase III
Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
NICE rejects Tarceva maintenance treatment
June 17, 2010Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer
Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …
Antisoma cancer drug fails in phase III
March 29, 2010Research and Development Antisoma, NSCLC, lung cancer
UK biotech Antisoma has suffered a disappointing late-stage failure with a potential lung cancer treatment it was developing with Novartis. …
Tarceva gets nod for maintenance treatment
March 22, 2010Sales and Marketing Tarceva, lung cancer
Tarceva looks set to gain approval in Europe to treat patients with non-small cell lung cancer whose disease remains stable …
Novartis buys into Transgene’s lung cancer candidate
March 11, 2010Research and Development Novartis, Transgene, immunotherapy, lung cancer
French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …
New approaches in lung cancer
January 1, 2010Sales and Marketing lung cancer
Lung cancer is the most common cancer in the world, with 1.3 million new cases diagnosed every year. The vast …
Avastin approved as first-line treatment for lung cancer
August 24, 2007Sales and Marketing avastin, lung cancer
Roche's cancer drug Avastin has gained European approval as a first-line treatment for lung cancer on the back of data …
NICE judges Tarceva too expensive for NHS
March 9, 2007Sales and Marketing Tarceva, lung cancer
Roche's cancer drug Tarceva has been rejected by NICE for use against the most common form of lung cancer.The watchdog …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
